Skip to main content
TipRanks
Go Ultimate75% OFF

Curis (CRIS) AI Stock Analysis

1,705 Followers
CRIS

Curis

(NASDAQ:CRIS)

Select Model
Rating:45Neutral
Price Target:$0.60â–²(27.72% Upside)
Action:reiterated
Date:11/19/26

The score is held down primarily by weak financial performance (sharp TTM revenue decline, large ongoing losses, and significant cash burn) and a weak longer-term technical trend (price below the 50/100/200-day averages with negative MACD). Offsetting some of this is a more constructive earnings-call outlook driven by encouraging PCNSL response data and stated progress toward enrollment and a potential accelerated approval path, though liquidity and listing-risk events remain material concerns.

Positive Factors
Strong PCNSL clinical activityThe reported PCNSL response rates indicate meaningful clinical activity in both untreated and salvage settings, supporting the relevance of emavusertib in a difficult oncology market. If maintained with additional follow-up, these results could strengthen partnering potential and regulatory prospects.
Negative Factors
Severe revenue and profitability weaknessThe sharp revenue decline and very large operating loss show that Curis currently lacks a commercial revenue base capable of supporting its cost structure. Continued losses could restrict investment in the pipeline and make future progress increasingly dependent on financing or strategic transactions.

Curis (CRIS) vs. SPDR S&P 500 ETF (SPY)

-100%-75%-50%-25%0%25%CRIS-97.92%SPY+9.80%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.20M
Dividend Yield
―
Average Volume (3M)
4.18M
Price to Earnings (P/E)
-0.1
Beta (1Y)
2.22
Revenue Growth
-90.23%
EPS Growth
91.34%
Country
US
Employees
22
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Curis Business Overview & Revenue Model

Company Description

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inh...

Curis Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q3-2026)|% Change Since:-17.86%|Next Earnings Date:May 06, 2025
Earnings Call SentimentPositive

The call was predominantly optimistic, driven by strong and consistent PCNSL response data, progress toward full enrollment and potential accelerated approval submissions, the upcoming CLL data readout, and a stated cash runway into 2027. The main negatives were the higher year-to-date net loss, limited cash balance, choppy enrollment in the ultra-orphan PCNSL indication, and the fact that CLL efficacy data remain pending.

Positive Updates

Strong PCNSL Response Rate in BTK-Inhibitor-Naive Patients
Updated TakeAim Lymphoma Study data showed an 86% response rate in BTK-inhibitor-naive PCNSL patients, with 6 of 7 patients responding. Management noted that published PCNSL studies of BTK inhibitors generally reported response rates of 39% to 67%.

Negative Updates

Higher Net Loss for the Quarter
Third-quarter net loss increased to $8.1 million, or $1.94 per share, from $7.7 million, or $9.86 per share, in the third quarter of 2025. The net loss increased by approximately 5.2% on a dollar basis.

Company Guidance

Curis expects to be fully enrolled in the PCNSL registrational study by the end of 2027, with 10 to 15 more patients needed, and, assuming that happens, anticipates filing for NDA for the accelerated approval in 2028 after following patients for probably 6 months from last patient in; responses are typically obtained in the first few cycles, the hurdle is generally a 20% ORR, and only a couple of responses are needed in order to hit the hurdle. In CLL, the company remains on track to report initial clinical data by year-end, with 12 patients on study across 11 clinical sites, including patients on drug for 3 or 4 cycles and potentially some patients with data for only a cycle or 2. Based on its current operating plan, Curis believes its existing cash and cash equivalents, along with the financing from October, should enable it to fund existing operations into '27.

Curis Financial Statement Overview

Summary

Income statement and cash flow are weak: TTM revenue fell sharply to about $1.1M with large ongoing losses (TTM EBIT about -$37.8M) and significant cash burn (TTM OCF/FCF about -$30.8M). The balance sheet shows modest leverage (debt-to-equity ~0.29, total debt ~$0.7M), but equity has compressed materially over time, reducing financial flexibility.

Income Statement

18Very Negative

Balance Sheet

44Neutral

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMDec 2025Mar 2025Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.14M9.44M10.91M10.02M10.16M10.65M
Gross Profit1.11M9.40M10.81M9.81M9.90M10.12M
EBITDA-22.90M-5.23M-42.57M-45.14M-51.67M-40.81M
Net Income-21.54M-7.58M-43.39M-47.41M-56.67M-45.44M
Balance Sheet
Total Assets18.80M19.97M41.27M77.28M108.85M162.30M
Cash, Cash Equivalents and Short-Term Investments5.01M5.06M20.00M56.33M85.62M115.88M
Total Debt740.00K1.62M2.95M2.79M3.94M5.04M
Total Liabilities16.25M14.50M47.26M57.61M62.30M71.59M
Stockholders Equity2.55M5.46M-6.00M19.67M46.55M90.71M
Cash Flow
Free Cash Flow-30.77M-27.20M-39.56M-38.43M-54.75M-37.62M
Operating Cash Flow-30.77M-27.20M-39.56M-38.43M-54.34M-37.62M
Investing Cash Flow2.50M2.50M29.44M37.79M33.02M-47.90M
Financing Cash Flow24.23M9.77M3.44M7.58M867.00K-4.17M

Curis Technical Analysis

Technical Analysis SentimentNeutral
Last Price0.47

Price Trends

50DMA0.72Negative
100DMA2.20Negative
200DMA7.89Negative

Market Momentum

MACD-0.06Negative
RSI47.61Neutral
STOCH18.99Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRIS, the sentiment is Neutral. The current price of 0.47 is below the 20-day moving average (MA) of 0.60, below the 50-day MA of 0.72, and below the 200-day MA of 7.89, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 47.61 is Neutral, neither overbought nor oversold. The STOCH value of 18.99 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CRIS.

Curis Risk Analysis

Curis disclosed 60 risk factors in its most recent earnings report. Curis reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks
1.Our July 2026 Reverse Stock Split may decrease the liquidity of our common stock.Q2, 2026
2.Item 5. OTHER INFORMATION Director and Officer Trading ArrangementsQ3, 2024
3.Item 5. OTHER INFORMATION Director and Officer Trading ArrangementsQ2, 2024

Curis Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CRIS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ATNMATNM59Neutral$33.96M3.2765.18%―38788.89%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
CLRBCLRB45Neutral$9.24M-0.24-154.53%――66.06%
CRISCRIS45Neutral$5.84M-0.10-339.08%―-90.23%91.34%
CNSPCNSP41Neutral$6.12M-0.24-166.03%――68.89%
NCNANCNA38Underperform$4.29M-0.20-51.04%―――

* Healthcare Sector Average

Performance Comparison

-50%0%CRISATNMCLRBNCNACNSPDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CRIS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CRISCuris Inc.0.47-22.93-98.00%
ATNMActinium Pharmaceuticals1.07-0.26-19.55%
CLRBCellectar Biosciences Inc0.88-1.98-69.16%
NCNANucana Plc0.72-2.78-79.49%
CNSPCns Pharmaceuticals, Inc.3.92-2.99-43.26%

Curis Corporate Events

Delistings and Listing ChangesStock Split

Curis Faces Nasdaq Delisting Risk After Bid-Price Deficiency

Negative
Nov 6, 2026

On November 2, 2026, Curis, Inc. received a Nasdaq delisting determination after its common stock’s bid price closed below the $1 minimum for 30 consecutive business days. Because Curis had completed a 1-for-20 reverse stock split on July 6, 2026, it...

Business Operations and StrategyPrivate Placements and Financing

Curis Secures PIPE Financing Through Securities Purchase Agreement

Positive
Oct 19, 2026

On October 16, 2026, Curis entered into a private securities purchase agreement with institutional investors to sell 16,666,680 shares of common stock or pre-funded warrants, plus matching common warrants, at an effective combined price of $0.51 per...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 19, 2026